| Filter Options | |||||
|---|---|---|---|---|---|
| Public title | Scientific title | Subject ID | |||
| Registration Status | Registration number | Secondary ID | |||
| Applicant | Study leader | Year | |||
| Primary sponsor | Secondary sponsor | Source(s) of funding | |||
| Target disease | Target disease code | Study type | |||
| Study phase | Study design | Study execute time |
From To |
||
| Recruiting status | Gender | Sign the informed consent | |||
| Countries of recruitment and research settings |
Nation(Area):Province:City: Institution:Level of the institution: |
||||
| Intervention | Intervention code | Approved by ethic committee | |||
|
Calculated Results after the Study Completed public access |
Statistical results after completion of the test file upload |
||||
| More Options | |||||
7 trials have been registered
| Historical versions | Registration number | Public title | Type | Registration time |
|---|---|---|---|---|
| Historical Versions | ChiCTR2000040924 |
Real-world efficacy and safety of Arbidol in the treatment of influenza-like illness Qilu Hospital of Shandong University |
Observational | 2020/12/15 |
| Historical Versions | ChiCTR2000029759 |
The Second Affiliated Hospital of Chongqing Medical University |
Interventional | 2020/02/12 |
| Historical Versions | ChiCTR2000029621 |
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
Interventional | 2020/02/07 |
| Historical Versions | ChiCTR2000029592 |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
Observational | 2020/02/05 |
| Historical Versions | ChiCTR1900028586 |
Shulan (Hangzhou) Hospital |
Interventional | 2019/12/28 |
| Historical Versions | ChiCTR1900022146 |
Arbidol for COPD Exacerbations: a randomized controlled trial Shengjing Hospital |
Interventional | 2019/03/27 |
| Historical Versions | ChiCTR-TRC-12001946 |
Pharmacokinetics of arbidol hydrochloride suspension in healthy Chinese volunteers Shengjing Hospital of China Medical University |
Interventional | 2012/02/03 |